PT  - JOURNAL ARTICLE
AU  - Ng, Dianna L.
AU  - Goldgof, Gregory M.
AU  - Shy, Brian R.
AU  - Levine, Andrew G.
AU  - Balcerek, Joanna
AU  - Bapat, Sagar P.
AU  - Prostko, John
AU  - Rodgers, Mary
AU  - Coller, Kelly
AU  - Pearce, Sandy
AU  - Franz, Sergej
AU  - Du, Li
AU  - Stone, Mars
AU  - Pillai, Satish K.
AU  - Sotomayor-Gonzalez, Alicia
AU  - Servellita, Venice
AU  - Martin, Claudia Sanchez San
AU  - Granados, Andrea
AU  - Glasner, Dustin R.
AU  - Han, Lucy M.
AU  - Truong, Kent
AU  - Akagi, Naomi
AU  - Nguyen, David N.
AU  - Neumann, Neil M.
AU  - Qazi, Daniel
AU  - Hsu, Elaine
AU  - Gu, Wei
AU  - Santos, Yale A.
AU  - Custer, Brian
AU  - Green, Valerie
AU  - Williamson, Phillip
AU  - Hills, Nancy K.
AU  - Lu, Chuanyi M.
AU  - Whitman, Jeffrey D.
AU  - Stramer, Susan
AU  - Wang, Candace
AU  - Reyes, Kevin
AU  - Hakim, Jill M.C.
AU  - Sujishi, Kirk
AU  - Alazzeh, Fariba
AU  - Pham, Lori
AU  - Oon, Ching-Ying
AU  - Miller, Steve
AU  - Kurtz, Theodore
AU  - Hackett, John
AU  - Simmons, Graham
AU  - Busch, Michael P.
AU  - Chiu, Charles Y.
TI  - SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area
AID  - 10.1101/2020.05.19.20107482
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.19.20107482
4099  - http://medrxiv.org/content/early/2020/05/27/2020.05.19.20107482.short
4100  - http://medrxiv.org/content/early/2020/05/27/2020.05.19.20107482.full
AB  - We report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seropositivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors. We additionally describe the longitudinal dynamics of immunoglobulin-G, immunoglobulin-M, and in vitro neutralizing antibody titers in COVID-19 patients. Neutralizing antibodies rise in tandem with immunoglobulin levels following symptom onset, exhibiting median time to seroconversion within one day of each other, and there is >93% positive percent agreement between detection of immunoglobulin-G and neutralizing titers.Competing Interest StatementCYC is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) and receives research support funding from Abbott Laboratories. JP, MD, KC, SP, and JRH, Jr. are employees of Abbott Laboratories. The other authors have no competing interests to declare.Funding StatementThis work was funded by NIH grants R01-HL105704 (CYC) from the National Heart, Lung, and Blood Institute, R33-129077 (CYC) the National Institute of Allergy and Infectious Diseases, the Charles and Helen Schwab Foundation (CYC). These funders had no role in study design, data collection and analysis, writing the manuscript, or decision to publish. This work was also funded in part by Abbott Laboratories. Employees of Abbott laboratories (J.P., M.R., K.C., S.P., J.H.) contributed to sample collection, IgG and IgM testing, and data analysis but had no role in the study design, writing the manuscript, or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board (IRB) at UCSF (UCSF IRB #10-02598) as a no-subject contact study with waiver of consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data used in this study, including de-identified patient metadata and test results, are available upon request.